Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan for Weaning From VA-ECMO in Cardiogenic Shock
NCT04728932Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2021
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of levosimendan in cardiogenic shock, sponsored by Assistance publique - Hôpitaux de Paris. Started Aug 2021; status: completed.
02
Drugs
levosimendan
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on NCT04728932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04728932.